Although genetic predisposition is recognized and all cells carry the same mutation in a RET-carrier patient, not all cells in a given tissue undergo tumorigenesis processes and not all mutation carriers will develop endocrine cancers commonly related to MEN 2 phenotype. This evidence concerns the gene RET and malignant endocrine neoplasm.